Levocetirizine Dihydrochloride (CAS 130018-87-0)/Antihistamine

Levocetirizine Dihydrochloride (CAS 130018-87-0) is a high-purity pharmaceutical API classified as a potent third-generation antihistamine, featuring the R-enantiomer of cetirizine with high selectivity for peripheral H1 receptors. It exerts powerful anti-allergic effects by competitively blocking histamine binding, while inhibiting the release of allergy-related inflammatory mediators—delivering rapid relief from itching, sneezing, and rashes. Unlike first-generation antihistamines, it has minimal blood-brain barrier penetration, resulting in negligible sedation and a superior safety profile.

Presented as a white crystalline powder with excellent water solubility, it supports the development of oral tablets, capsules, and solutions. It caters to the core needs of anti-allergy drug manufacturers, dermatological formulation developers, and clinical supply chains. Widely applied in relieving symptoms of seasonal/perennial allergic rhinitis, chronic idiopathic urticaria, eczema, and skin pruritus, it aligns with demand for effective, non-sedating allergy therapies. Produced under strict GMP standards, each batch undergoes rigorous purity, bioactivity, and stability testing to meet international pharmacopoeia requirements, ensuring consistent clinical efficacy.